Barrett's Esophagus Clinical Trial
Official title:
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
Subjects enrolled in this study will have biopsies obtained and sent to Dr. Fitzgerald's lab for analysis of a validated biomarker panel. Subjects will be stratified to either high or low risk of progression to esophageal adenocarcinoma (EAC) based on biomarker panel results. Biomarker panel results will not be communicated to sites. Subjects with low grade dysplasia will be offered the option of treatment (radiofrequency ablation (RFA)) as part of routine care. Subjects with low grade dysplasia who do not want RFA and subjects with no dysplasia will receive surveillance endoscopy in 1 year per routine care. All subjects will be administered a questionnaire seeking information about hypothetical willingness to be randomized to treatment or surveillance.
The Investigators have previously completed a validation study in which they have identified
a panel of biomarkers that can predict progression of subjects with BE and no dysplasia or
low-grade dysplasia to esophageal adenocarcinoma (EAC). The biomarker panel, performed by
the Fitzgerald lab, included ploidy (by image cytometry), AOL (histochemistry (IHC)), p53
(IHC), cyclin A (IHC), and dysplasia. These markers have been validated and demonstrated to
be highly predictive of both progression to EAC, as well as the presence of occult
malignancy elsewhere in the specimen (field effect). The final panel of validated biomarkers
will be used in this study to identify patients at high risk of developing EAC.
The study will recruit 100 patients across 4 sites (University of North Carolina, Case
Western Reserve University, University of Cambridge, and Academic Medical Center in
Amsterdam). The specific aims of this pilot study are to:
1. Demonstrate that the international, multicenter team can work together,
2. Define the logistics of assaying biomarkers in real time such that in the future
interventional trial, results could influence clinical decision-making, and,
3. Provide further data to inform a power calculation for the full trial.
Subjects enrolled in the study will complete a questionnaire gathering hypothetical
willingness to be randomized to receive endoscopic treatment intervention (RFA) or
surveillance endoscopy.
Biopsy samples will be obtained from all subjects and tested for all biomarkers in the
panel. Results of the biomarker panel will not be communicated to sites. Subjects with low
grade dysplasia will be offered the option of receiving radiofrequency ablation (RFA) as
part of routine care. Subjects with low grade dysplasia who agree to RFA will receive RFA as
part of routine care. Subjects with no dysplasia and subjects with low grade dysplasia who
do not want to receive RFA will receive a surveillance endoscopy in 1 year as part of
routine care.
The goals of this pilot study are to ascertain the proportion of subjects in the high risk
arm, to demonstrate the plausibility of performing the biomarker analysis efficiently in a
sizable group of patients, to demonstrate the feasibility of delivering the endoscopic
intervention (RFA), to obtain 1 year pilot data regarding progression in the high risk arm
for use in sample size calculations, and to document collaboration among the centers.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02864043 -
Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System
|
N/A | |
Recruiting |
NCT02018367 -
Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma
|
Phase 2 | |
Terminated |
NCT01572987 -
Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus
|
N/A | |
Terminated |
NCT01976351 -
Imaging Enhanced Endoscopy for the Screening of Barrett's Esophagus
|
N/A | |
Terminated |
NCT00526786 -
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
|
Phase 4 | |
Completed |
NCT01401699 -
Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction
|
N/A | |
Completed |
NCT02106910 -
Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy
|
N/A | |
Suspended |
NCT01580631 -
Narrow Band Imaging Project on Barrett's Esophagus
|
||
Completed |
NCT01439633 -
Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus
|
N/A | |
Completed |
NCT02879721 -
Expression and Function of the Renin-Angiotensin System in the Esophagus
|
Phase 0 | |
Completed |
NCT01439594 -
Optical Frequency Domain Imaging (OFDI) Assessment in Radiofrequency Ablation
|
N/A | |
Completed |
NCT01281618 -
Influence of Acid Reflux on Stromal Epithelial Interaction in Barrett's Esophagus
|
N/A | |
Completed |
NCT00586872 -
Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus
|
||
Completed |
NCT00844077 -
Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus
|
N/A | |
Completed |
NCT00588575 -
Ramanspectroscopy in Barrett's Esophagus
|
||
Recruiting |
NCT00288119 -
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
|
||
Completed |
NCT03813381 -
CAlorie and Protein REstriction PROgram in Barrett's Esophagus Patients (CARE-PRO).
|
N/A | |
Completed |
NCT02579460 -
Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition
|
N/A | |
Completed |
NCT01961778 -
Comparison of Treatments for Barrett's Esophagus With High-Grade Dysplasia/Early Adenocarcinoma
|
N/A | |
Not yet recruiting |
NCT02033070 -
Patient Registry: Radio Frequency Ablation of Barrett's Esophagus Using HALO System
|
N/A |